

RECEIVED
CENTRAL FAX CENTER

001/027

OFFICIAL

AUG 17 2004

PTO/SB/21 (02-04)

Approved for use through 07/31/2009. OMB 0651-0001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10005,646
	Filing Date	12/7/2001
	First Named Inventor	Peter W. BRINGMANN
	Art Unit	1847
	Examiner Name	Christine J. SAOUJ
	Attorney Docket Number	51835AU/SM1
Total Number of Pages in This Submission		27

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Associate Power of Attorney
Remarks This document is being faxed to Central Facsimile Number 703 872-9306		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Anne Gil, Registration No. 48,728	
Signature	<i>Anne Gil</i>	
Date	August 17, 2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Anne Gil	
Signature	<i>Anne Gil</i>	Date
		August 17, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re to the Application of: Peter W. BRINGMANN et al. Serial No.: 10/005,646 Filed: 7 December 2001 Title: NOVEL FIBROBLAST GROWTH FACTORS Docket No.: 51835AUSM1	Examiner: Christine J. Saoud Group Art Unit: 1647
--	--

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO OFFICE ACTION

Dear Sir:

This communication is responsive to the Office Action mailed 17 March 2004, in the above-referenced application. Applicants respectfully request consideration of the following remarks and amendments responsive to this Office Action.

A request for a two-month extension for responding to this Office Action is enclosed herewith, making the due date for responding to the Office Action, 17 August 2004.

The Commissioner is hereby authorized to charge any fees associated with this response, or credit any overpayment, to Deposit Account No. 02-2117.

AMENDMENTS

In the Claims:

Please cancel Claims 1-35, 42-68, and 70, because the claims have been withdrawn from consideration under 37 CFR 1.142(b), as allegedly being drawn to a non-elected invention. A clean copy of the pending claims as amended are attached herewith in the Appendix.

Please amend Claims 36, 39, 40, and 41 as follows:

36. (Once Amended) A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by [ischemic attack, infarction, hemorrhage or aneurysm; Huntingtons' disease;] multiple sclerosis; myelopathy; myelitis; or syringomyelia], comprising administering to a patient in need thereof an effective amount of an FGF-9 polypeptide or a biologically active fragment thereof.

39. (Once Amended) The method of Claim 36, wherein said polypeptide comprises amino acid 1 to amino acid 208 as set forth in Fig. 3 (SEQ ID NO: 5).